BofA analyst Alec Stranahan lowered the firm's price target on Perspective Therapeutics to $6 from $7 and keeps a Neutral rating on the shares. The Q1 report reinforced the progress of the radiopharmaceutical pipeline with "a slew of updates" expected in late-2026, the analyst tells investors.
